Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer

David J McConkey ¹, Brian C Baumann ^2,3, Stephanie Cooper Greenberg ⁴

¹Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
²Department of Radiation Oncology, Springfield Clinic, Springfield, IL, USA.
³Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
⁴Patient Advocate, Baltimore, MD, USA.
⁵Department of Pathology and Laboratory Medicine, Pennsylvania State University, Hershey, PA, USA.
⁶Department of Urology, Pennsylvania State University, Hershey, PA, USA.
⁷Department of Urology, Louisiana State University Health Science Center, New Orleans, New Orleans, LA, USA.
⁸Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁹Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA.
¹⁰Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
¹¹US Medical Affairs and Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
¹²Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
¹³Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
¹⁴Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
¹⁵Convergent Genomics, San Francisco, CA, USA.
¹⁶Department of Urology, Stanford University, Stanford, CA, USA.
¹⁷Department of Urology, Feinberg School of Medicine, Chicago, IL, USA.
¹⁸Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Chicago, IL, USA.
¹⁹Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA, USA.
²⁰Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
²¹Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²²Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²³Department of Urology, Ohio State University Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, OH, USA.
²⁴Coordinating Center for Clinical Trials, National Cancer Institute, NIH, Bethesda, MD, USA.
²⁵Emmes Company, Rockville, MD, USA.
²⁶University of North Carolina at Chapel Hill, Departments of Pathology and Laboratory Medicine and Urology, Chapel Hill, NC, USA.
²⁷Vancouver Prostate Centre, Department of Urologic Sciences,University of British Columbia, Vancouver, BC, Canada.
²⁸Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
²⁹Genitourinary Malignancies Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA.
³⁰University of British Columbia, Vancouver, BC, Canada.

⁰Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.

Bladder Cancer +

|

July 12, 2024

Summary

No abstract available on PubMed